Lonza’s Post

#Preclinical researchers in #IPF ( Idiopathic Pulmonary Fibrosis ) >> By reducing the mortality rate from an industry average of 40% to 20%, while maintaining significant and reproducible results, our IPF disease model provides valuable insights to biopharm and biotech companies far more quickly, saving valuable therapeutic discovery and development time and money. Learn more >> https://lnkd.in/gsBchHBF #MLMAdvantage #diseasemodels #preclinicalresearch

📣 𝐅𝐃𝐀 𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐬 𝐑𝐞𝐳𝐝𝐢𝐟𝐟𝐫𝐚, 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐟𝐨𝐫 𝐍𝐀𝐒𝐇/𝐌𝐀𝐒𝐇📣 About a week ago, FDA approved the very first treatment for patients with liver fibrosis caused by fatty liver disease. Rezdiffra (resmetirom) is now approved for treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise. While this is a significant milestone in the research area of NAFLD/NASH, many additional steps remain for all stakeholders in the field before establishing access to treatments for patients in Europe. Quantify Research has several years of experience in conducting research on a globally unique NAFLD dataset, which is fit-for-purpose to support a broad range of strategic and scientific evidence gaps for multiple actors. For more information, please visit our website! https://lnkd.in/dxt5wrM2 Quantify Research info@quantifyresearch.com www.quantifyresearch.com

There's still time to register for this expert webinar! » https://bit.ly/3wEFJta The world of drug development is evolving with the increased acceptance of real-world evidence (RWE). Disease registries, one of the most clinically rich sources of real-world data (RWD), are at the forefront of this change. These registries are purpose-built for research, allowing the collection of fit-for-purpose data, especially in rare diseases. Register for this expert webinar to gain insights into how RWE and RWD from registries enhance clinical development, approval and post-marketing analyses, particularly for rare diseases.

We are excited to announce our latest partnership with n-Lorem Foundation to develop personalized antisense oligonucleotide (ASO) treatments for patients with ultra-rare and nano-rare diseases. In many cases, nano-rare patients will succumb to their disease without ever having hope of a treatment that will halt their progressive diseases. But working with n-Lorem, we hope to change this. We will provide amidites, compounds essential to developing ASO medicines, to n-Lorem to help offset the costs of developing ASO medicines for up to 20 nano-rare patients. Learn more from Wei Jiang and Stanley Crooke about this exciting partnership below. 👇 https://loom.ly/zDaQhRk #RareDiseases #DrugDevelopment #Oligonucleotides

June has been Myasthenia Gravis (#MG) Awareness Month, a time dedicated to raising awareness of MG, a chronic neuromuscular autoimmune disease that affects a person’s ability to control their muscles, causing fatigue and muscle weakness. This #NeuromuscularDisease affects over 70,000 people in the United States alone, and 20 out of every 100,000 people worldwide. NMD Pharma is dedicated to developing treatments for MG, with an ongoing Phase 2b #ClinicalTrial of NMD670, our lead small molecule oral inhibitor of the skeletal muscle-specific CIC-1 ion channel that aims to enhance skeletal muscle activation and improve muscle function with potential to allow patients living with the disease to live better, more independent lives. We were happy to announce several weeks ago, in this MG Awareness Month, that our first patient was enrolled in this important study. It’s important to understand the challenges faced by those affected by MG and work together to continue to raise awareness and support those living with this disease, not only in June, but throughout the whole year. Please stay tuned throughout the year for more MG news and programs from NMD Pharma and others who are dedicated to help those affected by MG. #NMDPharma #MyastheniaGravis #MyastheniaGravisAwarenessMonth #Biotech #Innovation #RareDisease

I am happy to share with you a newly published Original Article today! 👃 Topic: Dupilumab treatment for severe chronic rhinosinusitis with nasal polyps: efficacy and impact on co-existing mild to moderate asthma ✍ Authors: Niki Papapostolou, Michael Makris 🗨 Keywords: #Asthma, #chronic rhinosinusitis with nasal polyps (CRSwNP), #dupilumab, #biologic agent, #type 2 inflammation Read the full text at https://lnkd.in/gUzvJyuQ Download the PDF at https://lnkd.in/gsTuK2JA This article belongs to the special issue "Eosinophilic inflammation: Severe asthma and beyond" edited by Prof. Nikoletta Rovina, Assistant Prof. Andriana Papaioannou and Prof. Petros Bakakos. For more details of this special issue at https://lnkd.in/grBBmUcQ

Single center study of 163 pts (mostly RA) Rx w/ tocilizumab found 41 hospitalized & 49% for serious infx. SIE were more common w/ eosinopenia (EC < 0.05 g/L; avg (0.06 vs 0.20 g/L) & low ratio EC/NC ratio (× 1000 < 11.8) (median (6.54 vs 48.50).

Sepsis affects 48.9 million people annually, leading to 11 million deaths worldwide.* Research has shown that biomarkers like pancreatic stone protein (PSP) can improve sepsis diagnostic accuracy. PSP can also help with the guidance of effective treatment at a time where antibiotic resistance and healthcare costs are becoming greater challenges. Find out more by visiting: https://lnkd.in/ePKMnR73 *VenturaF, Eggimann P, et all., Medical Research Archives, 2023 #healthcare #PSP #sepsis #australia #newzealand

🚨 Only 2 weeks to go! 🚨 Use code RARE20 for 20% discount. Join us at the Rare Diseases Industry Accelerator Day on October 1, 2024, at The Francis Crick Institute, London, from 9:00 AM - 5:30 PM followed by a networking drinks reception. This is a must-attend event for professionals across the rare diseases landscape, including #clinicians, #researchers, #biotech leaders, and #patient advocates. Together, we'll explore how to accelerate the development of life-changing therapies for rare diseases. With expert-led sessions on innovation, #precision medicine, and breakthrough regulatory frameworks, this event will forge new collaborations and strategies to tackle the challenges of rare disease treatment. 💡Gain insights on drug development pathways, data-driven decisions, and cutting-edge therapies. 🌍Network with key stakeholders driving transformational change Limited tickets available! 🎟 Secure yours now and be part of the future of rare disease treatments ⌛ https://lnkd.in/ezN7RDuz 📑 Download agenda --> https://lnkd.in/gGEMdkzV #RareDisease #PCD #LifeSciences #Innovation #DrugDevelopment #PersonalisedMedicine #HealthcareInnovation

I am happy to share with you a newly published Original Article today! 👃 Topic: Dupilumab treatment for severe chronic rhinosinusitis with nasal polyps: efficacy and impact on co-existing mild to moderate asthma ✍ Authors: Niki Papapostolou, Michael Makris 🗨 Keywords: #Asthma, #chronic rhinosinusitis with nasal polyps (CRSwNP), #dupilumab, #biologic agent, #type 2 inflammation Read the full text at https://lnkd.in/gUzvJyuQ Download the PDF at https://lnkd.in/gsTuK2JA This article belongs to the special issue "Eosinophilic inflammation: Severe asthma and beyond" edited by Prof. Nikoletta Rovina, Assistant Prof. Andriana Papaioannou and Prof. Petros Bakakos. For more details of this special issue at https://lnkd.in/grBBmUcQ